Innovative HPV RNA Sequencing Test Set to Revolutionize Cervical Cancer Screening
Woippy, France – 2025-06-25 – ABL diagnostics, a French molecular diagnostics company, has licensed an innovative Human Papillomavirus (HPV) RNA sequencing test (HPV RNA-SEQ) from the Pasteur Institute. This agreement aims to enhance the detection and genotyping of precancerous cervical lesions linked to HPV infections, potentially revolutionizing cervical cancer screening and patient care.
Next-Generation HPV Detection Technology
The HPV RNA-SEQ test,developed by the Pasteur Institute,is a next-generation molecular test designed to identify precancerous lesions of the cervix using cervical samples. This advanced test combines the benefits of molecular testing and cervical cytology through reverse transcription PCR (RT-PCR) coupled with new generation sequencing (NGS). This method offers a significant advancement over current HPV infection tests, promising more accurate detection and characterization of HPV types.
Did You Know? Cervical cancer is the fourth most common cancer in women globally, with approximately 570,000 new cases diagnosed annually [World Cancer research Fund].
Partnership for Innovation
The development of this technology was supported by the Pasteur Institute’s innovation accelerator, which provides financing, technical support, and commercial expertise to advance scientific discoveries. The licensing agreement with ABL Diagnostics, a leader on Euronext in molecular diagnostics, exemplifies a successful partnership between academic research and industry.
Dr. Isabelle Buckle, Director of research and industrial relations applications at the Institut Pasteur, stated, “This innovation demonstrates the efficiency of the pasteur Institute’s innovation accelerator and the importance of working with industrial partners to translate scientific discoveries into tangible health applications. The financing from the Carnot system was crucial in developing this advanced technology, which will help address the public health challenge of cervical cancer prevention.”
ABL Diagnostics: bringing Innovation to Market
ABL Diagnostics, established in 2016 and listed on Euronext, specializes in genotyping tests for infectious diseases. The company integrates the entire process from R&D to marketing. ABL Diagnostics serves university clinical pathology laboratories, private reference laboratories, and researchers seeking innovative microbiological solutions. in 2024, the company achieved a turnover of 5.3 million euros.
Pro Tip: Regular cervical cancer screening, including Pap tests and HPV tests, is essential for early detection and prevention [CDC].
The Importance of HPV Screening
Cervical cancer is almost always caused by high-risk HPV infections [1]. HPV tests can detect these high-risk strains, allowing for early intervention and treatment to prevent the development of cervical cancer. The new HPV RNA sequencing test promises to improve the accuracy and efficiency of this screening process.
| Organization | Role | Contribution |
|---|---|---|
| pasteur Institute | Research Institution | Developed the HPV RNA-SEQ test |
| ABL Diagnostics | Diagnostics Company | Will produce and market the test |
| Carnot Institute | scientific Excellence Label | Provided support and financing |
What impact do you think this new HPV RNA sequencing test will have on cervical cancer rates? How can we improve access to cervical cancer screening in underserved communities?
Evergreen Insights: Understanding HPV and Cervical Cancer
Human Papillomavirus (HPV) is a common virus that can cause various health problems, including cervical cancer. there are over 200 types of HPV,but only some are linked to cancer. Persistent infection with high-risk HPV types can lead to abnormal cell changes in the cervix, which, if left untreated, can develop into cervical cancer [American Cancer Society].
Cervical cancer is the fourth most common cancer in women worldwide [WHO]. However, it is also one of the most preventable cancers, thanks to effective screening programs and HPV vaccines. Regular screening,including Pap tests and HPV tests,can detect precancerous changes early,allowing for timely treatment and prevention of the disease.
Frequently Asked Questions About HPV and cervical Cancer
What is HPV?
HPV stands for Human Papillomavirus, a group of related viruses that can cause infections in the skin and mucous membranes.
How is HPV transmitted?
HPV is primarily transmitted through sexual contact.
What is cervical cancer?
cervical cancer is a type of cancer that occurs in the cells of the cervix, the lower part of the uterus that connects to the vagina.
How can cervical cancer be prevented?
Cervical cancer can be prevented through HPV vaccination and regular screening tests, such as Pap tests and HPV tests.
What are the symptoms of cervical cancer?
Early-stage cervical cancer may not cause any symptoms. As the cancer progresses, symptoms may include abnormal vaginal bleeding, pelvic pain, and pain during intercourse.
Disclaimer: this article provides general details and should not be considered medical advice. Consult with a healthcare professional for personalized guidance.
Share this article to raise awareness about cervical cancer prevention and the importance of early detection. Leave a comment below with your thoughts on this innovative technology!
